SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-21-012036
Filing Date
2021-04-07
Accepted
2021-04-07 17:18:33
Documents
3
Period of Report
2021-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10022864_8k.htm 8-K 33868
2 EXHIBIT 10.1 brhc10022864_ex10-1.htm EX-10.1 90704
3 EXHIBIT 99.1 brhc10022864_ex99-1.htm EX-99.1 9213
  Complete submission text file 0001140361-21-012036.txt   135444
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 21813005
SIC: 2834 Pharmaceutical Preparations